首页> 美国卫生研究院文献>Emerging Infectious Diseases >Acquired Resistance to Antituberculosis Drugs in England Wales and Northern Ireland 2000–2015
【2h】

Acquired Resistance to Antituberculosis Drugs in England Wales and Northern Ireland 2000–2015

机译:2000-2015年在英格兰威尔士和北爱尔兰获得的抗结核药耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Among tuberculosis (TB) patients, acquired resistance to anti-TB drugs represents a failure in the treatment pathway. To improve diagnosis and care for patients with drug-resistant TB, we examined the epidemiology and risk factors associated with acquired drug resistance during 2000–2015 among TB patients in England, Wales, and Northern Ireland. We found acquired resistance in 0.2% (158/67,710) of patients with culture-confirmed TB. Using multivariate logistic regression, we identified the following factors associated with acquired drug resistance: having pulmonary disease; initial resistance to isoniazid, rifampin, or both; a previous TB episode; and being born in China or South Africa. Treatment outcomes were worse for patients with than without acquired resistance. Although acquired resistance is rare in the study area, certain patient groups are at higher risk. Identifying these patients and ensuring that adequate resources are available for treatment may prevent acquisition of resistance, thereby limiting transmission of drug-resistant strains of mycobacteria.
机译:在结核病(TB)患者中,获得的抗结核药物耐药性代表治疗途径的失败。为了改善对耐药结核病患者的诊断和护理,我们检查了英格兰,威尔士和北爱尔兰2000-2015年期间与耐药性相关的流行病学和危险因素。我们在培养证实为TB的患者中发现了0.2%(158 / 67,710)的获得性耐药。使用多元逻辑回归分析,我们确定了与获得性耐药相关的以下因素:患有肺部疾病;最初对异烟肼,利福平或两者同时耐药;先前的结核病发作;并出生在中国或南非。有先天性抵抗的患者的治疗结果要比没有获得性抵抗的患者的治疗结果差。尽管获得性耐药在研究区域很少见,但某些患者群体的风险较高。确定这些患者并确保有足够的治疗资源可防止获得抗药性,从而限制分枝杆菌耐药菌株的传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号